It’s still a bull thesis, just subverted: Harmony Biosciences Holdings Inc (HRMY)

At the time of writing, Harmony Biosciences Holdings Inc [HRMY] stock is trading at $35.31, down -0.70%. An important factor to consider is whether the stock is rising or falling in short-term value. The HRMY shares have gain 4.50% over the last week, with a monthly amount glided 16.46%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Previously, Deutsche Bank started tracking the stock with Buy rating on February 11, 2025, and set its price target to $55. On December 17, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $75 on the stock. UBS initiated its recommendation with a Buy and recommended $56 as its price target on September 10, 2024. Citigroup started tracking with a Buy rating for this stock on June 21, 2024, and assigned it a price target of $48. In a note dated January 02, 2024, BofA Securities downgraded an Underperform rating on this stock but restated the target price of $30.

For the past year, the stock price of Harmony Biosciences Holdings Inc fluctuated between $26.47 and $41.61. Currently, Wall Street analysts expect the stock to reach $48 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $35.31 at the most recent close of the market. An investor can expect a potential return of 35.94% based on the average HRMY price forecast.

Analyzing the HRMY fundamentals

According to Harmony Biosciences Holdings Inc [NASDAQ:HRMY], the company’s sales were 744.85M for trailing twelve months, which represents an 19.48% jump. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.21%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.24 and Total Capital is 0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.66 points at the first support level, and at 34.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.89, and for the 2nd resistance point, it is at 36.46.

Ratios To Look Out For

It is important to note that Harmony Biosciences Holdings Inc [NASDAQ:HRMY] has a current ratio of 3.67. On the other hand, the Quick Ratio is 3.63, and the Cash Ratio is 2.79. Considering the valuation of this stock, the price to sales ratio is 2.72, the price to book ratio is 2.81 and price to earnings (TTM) ratio is 13.46.

Transactions by insiders

Recent insider trading involved JEFFREY G DIERKS, Former Officer, that happened on May 19 ’25 when 9844.0 shares were purchased. Former Officer, JEFFREY G DIERKS completed a deal on May 16 ’25 to buy 2292.0 shares. Meanwhile, Former Officer JEFFREY G DIERKS bought 5000.0 shares on May 12 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.